Orion Oyj B (ORNBV) - Total Liabilities
Based on the latest financial reports, Orion Oyj B (ORNBV) has total liabilities worth €726.20 Million EUR (≈ $849.00 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orion Oyj B - Total Liabilities Trend (2000–2024)
This chart illustrates how Orion Oyj B's total liabilities have evolved over time, based on quarterly financial data. See Orion Oyj B working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Orion Oyj B Competitors by Total Liabilities
The table below lists competitors of Orion Oyj B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Primo Brands Corporation
NYSE:PRMB
|
USA | $7.63 Billion |
|
Jyske Bank A/S
CO:JYSK
|
Denmark | Dkr708.46 Billion |
|
AGCO Corporation
NYSE:AGCO
|
USA | $7.36 Billion |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
Germany | €288.99 Billion |
|
Primerica Inc
NYSE:PRI
|
USA | $12.16 Billion |
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
Germany | €331.92 Billion |
|
Biomerieux SA
PA:BIM
|
France | €1.47 Billion |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
Greece | €64.85 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Orion Oyj B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Orion Oyj B (ORNBV) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.34 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orion Oyj B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orion Oyj B (2000–2024)
The table below shows the annual total liabilities of Orion Oyj B from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €624.10 Million ≈ $729.64 Million |
+13.78% |
| 2023-12-31 | €548.50 Million ≈ $641.25 Million |
-7.89% |
| 2022-12-31 | €595.50 Million ≈ $696.20 Million |
+62.66% |
| 2021-12-31 | €366.10 Million ≈ $428.01 Million |
-4.74% |
| 2020-12-31 | €384.30 Million ≈ $449.29 Million |
+49.94% |
| 2019-12-31 | €256.30 Million ≈ $299.64 Million |
-31.40% |
| 2018-12-31 | €373.60 Million ≈ $436.78 Million |
-0.59% |
| 2017-12-31 | €375.80 Million ≈ $439.35 Million |
-10.91% |
| 2016-12-31 | €421.80 Million ≈ $493.13 Million |
-6.78% |
| 2015-12-31 | €452.50 Million ≈ $529.02 Million |
-7.01% |
| 2014-12-31 | €486.60 Million ≈ $568.89 Million |
+4.62% |
| 2013-12-31 | €465.10 Million ≈ $543.75 Million |
+42.80% |
| 2012-12-31 | €325.70 Million ≈ $380.78 Million |
+16.70% |
| 2011-12-31 | €279.10 Million ≈ $326.30 Million |
+0.25% |
| 2010-12-31 | €278.40 Million ≈ $325.48 Million |
-3.33% |
| 2009-12-31 | €288.00 Million ≈ $336.70 Million |
+4.01% |
| 2008-12-31 | €276.90 Million ≈ $323.73 Million |
+94.73% |
| 2007-12-31 | €142.20 Million ≈ $166.25 Million |
-1.66% |
| 2006-12-31 | €144.60 Million ≈ $169.05 Million |
-73.95% |
| 2005-12-31 | €555.00 Million ≈ $648.85 Million |
-15.38% |
| 2004-12-31 | €655.90 Million ≈ $766.82 Million |
+4.29% |
| 2003-12-31 | €628.90 Million ≈ $735.25 Million |
-13.16% |
| 2002-12-31 | €724.20 Million ≈ $846.67 Million |
+167.33% |
| 2001-12-31 | €270.90 Million ≈ $316.71 Million |
+10.21% |
| 2000-12-31 | €245.80 Million ≈ $287.37 Million |
-- |
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more